Atrial fibrillation, thromboembolism, and haemostasis: causal or casual associations?

Paulus Kirchhof; Eric Schulze-Bahr

doi:10.1055/s-0037-1613423

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2003; 90(06): 973-975
DOI: 10.1055/s-0037-1613423

Editorial Focus

Schattauer GmbH

Atrial fibrillation, thromboembolism, and haemostasis: causal or casual associations?

Paulus Kirchhof

¹Department of Cardiology and Angiology of the Hospital of the University of Münster, Münster, Germany

,

Eric Schulze-Bahr

¹Department of Cardiology and Angiology of the Hospital of the University of Münster, Münster, Germany

²“Genetics of Arrhythmias”, Department ‘Molecular Cardiology’ of the Institute for Arteriosclerosis Research at the University of Münster, Münster, Germany

References
1 Zipes DP. The seventh annual Gordon K. Moe Lecture. Atrial fibrillation: from cell to bedside. J Cardiovasc Electrophysiol 1997; 8: 927-38.
2 Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med 2001; 250: 382-9.
3 Benjamin EJ, Wolf PA, D’Agostino RB. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
4 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.
5 Kirchhof P, Eckardt L, Loh P. et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002; 360: 1275-9.
6 AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
7 Van Gelder IC, Hagens VE, Bosker HA. et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
8 Carlsson J, Miketic S, Windeler J. et al. Randomzied trial of rate-control versus rhythm-control in paersistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1690-6.
9 Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. Br Med J 2002; 325: 1022-25.
10 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in. JAMA 2003; 290: 1049-56.
11 Vene N, Mavri A, Komelj K. et al. High D-dimer levels predict cardiovascular events in patients with chornic atrial fibrillation during oral coagulant therapy. Thromb Haemost 2003; 90: 1193-202.
12 Lip GY, Lip PL, Zarifis J. et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-31.
13 Sohara H, Amitani S, Kurose M. et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-12.
14 Berge E, Friis P, Sandset PM. Hemostatic activation in acute ischemic stroke. Thromb Res 2001; 101: 13-21.
15 Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33: 1763-71.
16 van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C, Grobbee DE. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb Haemost 2001; 85: 234-9.
17 Bots ML, Breteler MM, van Kooten F. et al. Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. Haemostasis 1998; 28: 216-22.
18 Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-33.
19 Poli D, Antonucci E, Cecchi E. et al. Thrombophilic mutations in high-risk Atrial Fibrillation patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. Thromb Haemost 2003; 90: 1188-92.
20 Ridker PM, Miletich JP, Stampfer MJ. et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
21 De Stefano V, Martinelli I, Mannucci PM. et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. New Engl J Med 1999; 341: 801-6.
22 Gehring NH, Frede U, Neu-Yilik G. et al. Increased efficiency of mRNA 3-prime end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001; 28: 389-92.
23 Souto JC, Mateo J, Soria JM. et al. Homo-zygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism. Haematologica 1999; 84: 627-32.
24 Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-6.
25 Kahn MJ. Hypercoagulability as a cause of stroke in adults. South Med J 2003; 96: 350-3.
26 Au WW, Oh HY, Grady J. et al. Usefulness of genetic susceptibility and biomarkers for evaluation of environmental health risk. Environ Mol Mutagen 2001; 37: 215-25.